Genetic Variation in OCT1 and Response to Metformin

Type 2 Diabetes Clinical Trial

Official title:

Genetic Variation in OCT1 and Response to Metformin

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00588172
• Other study ID #: 07-004310
• Secondary ID: OCT1 and metform
• Status: Withdrawn
• Phase: Phase 4
• First received: December 22, 2007
• Last updated: August 16, 2010
• Start date: June 2010
• Est. completion date: June 2011

Study information

• Verified date: August 2010
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Type 2 diabetes its microvascular and macrovascular complications have become a major global health problem. Metformin is often used as first-line therapy for this disorder given that it is cheap, may cause weight loss and does not have significant side-effects in healthy patients. On the other hand, as many as one third of all patients with type 2 diabetes initially treated with metformin never achieve a meaningful response to this intervention. Recently, genetic variation in the organic cation transporter 1 (Oct1) gene which encodes a protein, OCT1, mediating metformin uptake by the liver, its primary site of action, has been shown alter metformin action. In Oct1-deficient mice the glucose-lowering effects of metformin are completely abolished. Moreover a polymorphism with a 20% minor allele frequency in Caucasians also alters the effect of metformin on glucose tolerance (the net result of glucose uptake and glucose release) after ingestion of 75g of glucose. However, it is unknown if this polymorphism affects suppression of endogenous glucose production or stimulation of peripheral glucose uptake by metformin, or both, and to what degree. We propose to utilize established methodology to measure glucose turnover in response to a mixed meal to determine how common genetic variation in OCT1 alters response to metformin in healthy volunteers. This will clarify the effect of these variants on response to metformin in humans. The knowledge gained from this study will help to design future studies examining the role of OCT1 genotype in determining initial therapy for type 2 diabetes.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2011
• Est. primary completion date: June 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria: -

1. Heterozygous or homozygous for the nsSNPs R61C, G401S, 420Del, G465R, G174S (see supplementary info (3)) or without any nsSNPs that could potentially alter gene function.

2. Age 18 - 40.

3. Willingness to participate in this study.

Exclusion criteria: -

1. Fasting glucose > 100mg/dL on one occasion.

2. Use of medication other than stable thyroid hormone replacement or oral contraception.

3. Subjects must not be pregnant or < 6 months postpartum at the time of study.

4. Prior abdominal surgery other than hysterectomy, appendectomy or tubal ligation.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• Metformin
1000mg bid for 1 week

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in glucose area under the curve after a mixed meal in response to metformin		before and after 1 week of metformin	No
Secondary	Change in glucose disappearance and suppression of endogenous glucose production in response to metformin		before and after 1 week of metformin therapy	No

External Links

•   Mayo Clinic Clinical Trials